Interestingly, our data showed that at a complete disappearance of the pAKT signal, as well as a significant decrease in c-MYC oncoprotein staining at relapse compared to what was observed at the diagnosis of mTNBC (Figure 4B,C, respectively), suggesting that the therapies administered to the patient had a significant impact in modulating cell survival and proliferation via negative regulation of pAKT, and cell cycle progression via the decrease of c-MYC, an oncoprotein often deregulated in cancer. Here, MYC is linked to cancer.